Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50-Day Moving Average – Should You Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB) shares passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $4.20 and traded as low as $2.40. Seres Therapeutics shares last traded at $2.53, with a volume of 24,613 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on MCRB shares. Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. Wall Street Zen upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. HC Wainwright began coverage on Seres Therapeutics in a research report on Tuesday, June 23rd. They set a “buy” rating and a $12.00 price objective on the stock. Finally, Zacks Research raised shares of Seres Therapeutics to a “hold” rating in a research note on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.00.

Seres Therapeutics Trading Down 2.8%

The business has a 50-day moving average price of $4.15 and a 200 day moving average price of $6.06. The stock has a market capitalization of $24.71 million, a P/E ratio of -1.01 and a beta of 0.31.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.47 EPS for the quarter, beating the consensus estimate of ($2.18) by $2.65. Seres Therapeutics had a negative net margin of 1,192.94% and a negative return on equity of 114.82%. The business had revenue of $0.74 million during the quarter, compared to analyst estimates of $0.18 million. On average, sell-side analysts predict that Seres Therapeutics, Inc. will post -6.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Seres Therapeutics

A hedge fund recently bought a new stake in Seres Therapeutics stock. Integrated Wealth Concepts LLC purchased a new stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,000 shares of the biotechnology company’s stock, valued at approximately $32,000. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutics designed to restore and maintain the function of the human microbiome. Its research has centered on therapeutic products made from defined mixtures of microorganisms, rather than conventional broad-spectrum antibiotics or nonselective fecal material.

The company’s leading product is VOWST, an orally administered microbiota-based therapy approved by the U.S. Food and Drug Administration for preventing the recurrence of Clostridioides difficile infection in adults following antibacterial treatment for recurrent infection.